GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma.
GlaxoSmithKline's inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug.
GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.
The approximate 1 in 10 asthma patients who have severe disease do not respond to mainstay corticosteroid treatment, even in high doses. That could be because the immune response that occurs in the airways of severe asthma patients markedly differs from what is seen in mild-moderate disease, a team of researchers recently posited.
The U.S. Food and Drug Administration today approved the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation.
Anoro Ellipta, a novel inhaler containing a long-acting muscarinic receptor antagonist and a selective long-acting beta-2 adrenergic receptor agonist, may find a limited place in therapy for a small group of patients.
The strength of the inhaled corticosteroid (ICS) in the combination inhaler Relvar Ellipta has been highlighted in an evidence summary on the medicine’s use in asthma, produced by the National Institute for Health and Care Excellence. Concerns about the dosing of the product and also the colour and name, were previously raised by a group of respiratory pharmacists in a letter to The Journal.